8-K: Certara Appoints IQVIA Veteran Jon Resnick as New CEO

Certara, a global leader in model-informed drug development, announced the appointment of Jon Resnick as its new Chief Executive Officer, effective January 1, 2026, succeeding Dr. William F. Feehery.

Summary

• Jon Resnick has been appointed as Certara's Chief Executive Officer and a Class III member of the Board of Directors, effective January 1, 2026.
• Dr. William F. Feehery will depart from his role as CEO and Board member at the close of business on December 31, 2025.
• Mr. Resnick, 53, brings over 20 years of experience from IQVIA Holdings Inc., where he most recently served as President for the U.S. and Canada regional business since July 2019.
• Mr. Resnick's compensation package includes an initial annual base salary of $750,000, an annual target bonus opportunity of 100% of his base salary, and a make-whole restricted stock unit grant with a target value of $6,500,000.
• He will also receive a pro-rata 2025 long-term incentive award with a target value of $4,000,000 and a 2026 long-term incentive award with a target value of $8,000,000.
• Dr. Feehery's departure is treated as a termination without cause, and he will provide transition services for a consulting fee of $20,000 per month, along with pro-rata vesting of his May 2025 equity awards.
• Certara reaffirms its full year 2025 financial outlook as previously disclosed on November 6, 2025.

Sentiment

Score: 7

Explanation: The announcement of a new CEO with extensive industry experience from a major player like IQVIA is a positive strategic move. The reaffirmation of the financial outlook provides stability. However, the departure of the previous CEO, who oversaw the IPO, introduces some uncertainty, balanced by a planned transition.

Positives

• The appointment of Jon Resnick, an executive with over two decades of leadership experience at IQVIA, a prominent global provider in life sciences, brings significant industry expertise to Certara.
• Mr. Resnick's background in building and scaling market leaders, advancing technological innovation, and fostering collaborative teams aligns well with Certara's strategic goals for growth in model-informed drug development.
• The company's reaffirmation of its full year 2025 financial outlook suggests stability and confidence in its current operational performance despite the leadership transition.
• A structured transition plan is in place, with Dr. Feehery serving as an external advisor, aiming to ensure a smooth handover of leadership.

Negatives

• The departure of Dr. William F. Feehery, who guided Certara through its successful IPO and reinforced its position as a global biosimulation leader, introduces a degree of uncertainty during the transition.
• The new CEO's compensation package includes a substantial make-whole restricted stock unit grant of $6,500,000 and significant long-term incentive awards, representing a considerable upfront and ongoing compensation commitment.

Risks

• Any deceleration in, or resistance to, the acceptance of model-informed biopharmaceutical discovery and development.
• Ability to compete effectively within the market.
• Changes or delays in government regulation relating to the biopharmaceutical industry.
• Trends in research and development (R&D) spending.
• The use of third parties by biopharmaceutical companies and a potential shift toward more R&D occurring at smaller biotechnology companies.
• Consolidation within the biopharmaceutical industry.
• Ability to successfully increase the customer base, expand relationships and the products and services provided, and enter new markets.
• Ability to retain key personnel or recruit additional qualified personnel.
• Risks related to the mischaracterization of independent contractors.
• Any delays or defects in the release of new or enhanced software or other biosimulation tools.
• Issues relating to the use of artificial intelligence and machine learning in products and services.
• Failure of existing customers to renew software licenses or any delays or terminations of contracts or reductions in scope of work by existing customers.
• Risks related to contracts with government customers, including the ability of third parties to challenge the receipt of such contracts.
• Ability to sustain historic growth rates.
• Any future acquisitions and the ability to successfully integrate such acquisitions.
• The accuracy of addressable market estimates.

Future Outlook

The company reaffirms its full year 2025 financial outlook as previously disclosed on November 6, 2025. The new CEO, Jon Resnick, expressed enthusiasm for leading Certara's next phase of growth, leveraging its AI, data, and simulation technologies to help clients reduce risk, accelerate timelines, and transform drug development.

Management Comments

• "We are excited to welcome Jon to Certara. He brings a proven track record of building and scaling market leaders, advancing technological innovation in healthcare and life sciences and fostering collaborative teams. We are confident that his leadership will help propel Certara to its next phase of growth and realize the full potential of model-informed drug development in accelerating medicines to patients." James E. Cashman III, Chairman of the Board of Directors.
• "I am thrilled to join Certara, a market-leading strategically important company at the forefront of innovation in drug discovery and development. Certara's suite of AI, data and simulation technologies, backed by a team of world-class experts, is uniquely positioned to drive long-term growth, while helping clients reduce risk, accelerate timelines and transform how medicines reach patients. I look forward to leading this talented team and helping our clients reach their goals." Jon Resnick.
• "The Board would like to thank Bill for his many contributions, including guiding Certara through its successful IPO, leading Certara's investment in software development and reinforcing its position as a global biosimulation leader. We are pleased that Bill will serve as an advisor to Certara to ensure a smooth transition." James E. Cashman III, Chairman of the Board of Directors.
• "I am incredibly proud of what we have accomplished at Certara. Together, we accelerated the adoption of biosimulation and helped our clients advance medicines with greater speed and confidence. As Certara enters its next chapter, this is the right moment for a leadership transition. I remain fully committed to supporting a smooth transition and am confident that Certara's future is exceptionally bright." Dr. William F. Feehery.

Industry Context

Certara operates in the dynamic life sciences and healthcare technology sectors, specializing in model-informed drug development and biosimulation. The appointment of Jon Resnick, with extensive experience from IQVIA—a global leader in clinical research services, commercial insights, and healthcare intelligence—signals a strategic emphasis on leveraging data, analytics, and technology-enabled services. This aligns with broader industry trends towards data-driven drug discovery, the integration of AI/ML, and the pursuit of greater efficiency in bringing new medicines to market. Resnick's background in real-world solutions and healthcare policy further positions Certara to navigate evolving regulatory landscapes and market demands, potentially enhancing its competitive stance against peers in the biopharmaceutical software and services space.

Comparison to Industry Standards

• Jon Resnick's recruitment from IQVIA, a 'global leader' in clinical research services and healthcare intelligence, indicates Certara's commitment to attracting top-tier talent with experience from large, established industry players. IQVIA's extensive operations provide a strong benchmark for the caliber of leadership experience sought.
• The compensation package for the new CEO, including a $6.5 million make-whole RSU grant and significant LTI awards, is competitive within the high-growth technology and life sciences sectors, reflecting the industry standard for attracting and retaining executive talent from major companies.
• The reaffirmation of the 2025 financial outlook suggests that Certara's performance is on track with previously communicated expectations, which is a standard measure of operational stability and investor confidence during a significant leadership transition in the industry.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact from new leadership with extensive industry experience, aiming for the 'next phase of growth.' The reaffirmation of the 2025 financial outlook provides short-term stability.
• Employees: A leadership transition can create uncertainty but also new opportunities under a new CEO. The new CEO's stated focus on 'fostering collaborative teams' could be a positive for employee morale and engagement.
• Customers: New leadership from IQVIA, a company focused on helping life sciences organizations, could lead to enhanced services and innovation in Certara's offerings, potentially benefiting clients in drug discovery and development.
• Creditors: The reaffirmation of the financial outlook suggests continued operational stability, which is generally positive for creditors, indicating the company is on track to meet its financial commitments.

Next Steps

• Jon Resnick will commence employment as CEO and join the Board of Directors on January 1, 2026.
• Dr. William F. Feehery will depart as CEO and Board member on December 31, 2025.
• Dr. Feehery will provide transition services to the company following his departure.
• Jon Resnick's term as a Class III Board member will expire at the Company's 2026 annual meeting of stockholders.
• From 2027 onward, Jon Resnick will be eligible for annual long-term incentive awards consistent with other senior executives of the Company.

Key Dates

Recommendation

The appointment of a new CEO with a strong background from IQVIA is a positive development, suggesting a focus on growth and innovation. The reaffirmation of the 2025 financial outlook provides stability. However, the departure of the previous CEO, who oversaw the IPO, introduces a degree of uncertainty during the transition period. Investors should hold to observe the new CEO's strategic direction and initial performance before making further investment decisions.

Keywords

Certara, CEO appointment, Jon Resnick, William Feehery, IQVIA, biosimulation, drug development, life sciences, executive change, corporate governance, financial outlook, Nasdaq: CERT